182 related articles for article (PubMed ID: 23844254)
1. p53 Aggregates penetrate cells and induce the co-aggregation of intracellular p53.
Forget KJ; Tremblay G; Roucou X
PLoS One; 2013; 8(7):e69242. PubMed ID: 23844254
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
3. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
5. Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain.
Kovachev PS; Banerjee D; Rangel LP; Eriksson J; Pedrote MM; Martins-Dinis MMDC; Edwards K; Cordeiro Y; Silva JL; Sanyal S
J Biol Chem; 2017 Jun; 292(22):9345-9357. PubMed ID: 28420731
[TBL] [Abstract][Full Text] [Related]
6. Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
Iwahashi N; Ikezaki M; Nishikawa T; Namba N; Ohgita T; Saito H; Ihara Y; Shimanouchi T; Ino K; Uchimura K; Nishitsuji K
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33225-33234. PubMed ID: 33318190
[TBL] [Abstract][Full Text] [Related]
7. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
8. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins.
Silva JL; Vieira TC; Gomes MP; Bom AP; Lima LM; Freitas MS; Ishimaru D; Cordeiro Y; Foguel D
Acc Chem Res; 2010 Feb; 43(2):271-9. PubMed ID: 19817406
[TBL] [Abstract][Full Text] [Related]
9. Fibrillar aggregates of the tumor suppressor p53 core domain.
Ishimaru D; Andrade LR; Teixeira LS; Quesado PA; Maiolino LM; Lopez PM; Cordeiro Y; Costa LT; Heckl WM; Weissmüller G; Foguel D; Silva JL
Biochemistry; 2003 Aug; 42(30):9022-7. PubMed ID: 12885235
[TBL] [Abstract][Full Text] [Related]
10. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
11. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
12. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells.
Münch C; O'Brien J; Bertolotti A
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3548-53. PubMed ID: 21321227
[TBL] [Abstract][Full Text] [Related]
13. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.
Herzog G; Shmueli MD; Levy L; Engel L; Gazit E; Klärner FG; Schrader T; Bitan G; Segal D
Biochemistry; 2015 Jun; 54(24):3729-38. PubMed ID: 26030124
[TBL] [Abstract][Full Text] [Related]
14. Prions, prion-like prionoids, and neurodegenerative disorders.
Verma A
Ann Indian Acad Neurol; 2016; 19(2):169-74. PubMed ID: 27293325
[TBL] [Abstract][Full Text] [Related]
15. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
16. Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?
Costa DC; de Oliveira GA; Cino EA; Soares IN; Rangel LP; Silva JL
Cold Spring Harb Perspect Biol; 2016 Oct; 8(10):. PubMed ID: 27549118
[TBL] [Abstract][Full Text] [Related]
17. Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer.
Pedrote MM; de Oliveira GAP; Felix AL; Mota MF; Marques MA; Soares IN; Iqbal A; Norberto DR; Gomes AMO; Gratton E; Cino EA; Silva JL
J Biol Chem; 2018 Jul; 293(29):11374-11387. PubMed ID: 29853637
[TBL] [Abstract][Full Text] [Related]
18. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
[TBL] [Abstract][Full Text] [Related]
19. Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.
Melo Dos Santos N; de Oliveira GAP; Ramos Rocha M; Pedrote MM; Diniz da Silva Ferretti G; Pereira Rangel L; Morgado-Diaz JA; Silva JL; Rodrigues Pereira Gimba E
J Biol Chem; 2019 Jun; 294(24):9430-9439. PubMed ID: 31028175
[TBL] [Abstract][Full Text] [Related]
20. Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity.
Hibino E; Tenno T; Hiroaki H
Front Mol Biosci; 2022; 9():869851. PubMed ID: 35558561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]